Business

Cannabics Pharmaceuticals Study Shows Complex Combinatorial Anti-tumor Activity of Cannabinoids

Cannabics Pharmaceuticals Study Shows Complex Combinatorial Anti-tumor Activity of Cannabinoids.

articleCnbx Pharmaceuticals Inc.March 25, 20205/company/cannabics-pharmaceuticals-inc/news/cannabics-pharmaceuticals-study-shows-complex-combinatorial-anti-tumor-activity-of-cannabinoids
Cannabics Pharmaceuticals Study Shows Complex Combinatorial Anti-tumor Activity of Cannabinoids

About this update from Cnbx Pharmaceuticals Inc.

[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Study Shows Complex Combinatorial Anti-tumor Activity of Cannabinoids\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Study Shows Complex Combinatorial Anti-tumor Activity of Cannabinoids\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, March 25, 2020\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, March 25, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that its R&D team in Israel studies the combinatorial effects of purified cannabinoids and has recently revealed complex relations between cannabinoid compounds, some of which bare synergistic effects and some antagonistic effects on the viability of gastrointestinal cancer cells.\n\n \n \n \n \n \n \n\n \nNatural cannabinoid extracts have been shown to have an entourage effect in various studies in different disease models and clinical studies. The overall view is that the entourage effect leads to better outcomes and purified cannabinoids are more toxic and less effective. However, the underlying combinatorial map of cannabinoids and their effects on cancer cell death remains undiscovered. \nCannabics' R&D team leverages its High Throughput Screening (HTS) platform to screen the necrotic effects of combinations of purified cannabinoids and builds a matrix to create proprietary new formulations. In this ongoing research on human gastrointestinal cancer cells, purified cannabinoids and their combinations are screened for antitumor effects. Up to date, most of the combinations reveal antagonistic effects and only few show synergisms.\nIn figure 1, a heat map of purified cannabinoid combinations shows high synergistic effect in killing gastrointestinal cancer cells only in combinations CB5+CB2. Names of cannabinoids are not present due to IP restrictions.\nDr. Eyal Ballan, CTO and Co-Founder, commented, \"We examine the efficacy of botanical extracts purified compounds and combinations in order to bet...

More updates from Cnbx Pharmaceuticals Inc.